KẾT QUẢ ĐIỀU TRỊ RỐI LOẠN LIPID MÁU BẰNG PITAVASTATIN Ở BỆNH NHÂN TĂNG HUYẾT ÁP NGUYÊN PHÁT TẠI BỆNH VIỆN TRƯỜNG ĐẠI HỌC Y DƯỢC CẦN THƠ

Abstract

Objectives: To evaluate the effect of pitavastatin on controlling LDL-c, HDL-c, and potential side effects in primary hypertensive patients at moderate or low cardiovascular risk. Subjects and Methods: A descriptive cross-sectional study was conducted on 50 primary hypertensive patients with dyslipidemia at the Department of Examination – Can Tho University of Medicine and Pharmacy Hospital. Results: The proportion of patients with LDL-c reaching the treatment target, as per the 2019 ESC guidelines, was 84%. Among them, 83.7% of patients at moderate cardiovascular risk and 85.7% of patients at low cardiovascular risk reached the LDL-c target. There was a 9.65% increase in HDL-c concentration. Regarding side effects, the rate of liver enzyme increases below 3 times the normal level was 30%. Conclusion: Pitavastatin demonstrates efficacy in controlling LDL-c and HDL-c with a high level of safety in primary hypertensive patients.